Agenda

MASTERCLASS WORKSHOPS
Tuesday, September 17, 2019
CONFERENCE DAY 1
Wednesday, September 18, 2019
CONFERENCE DAY 2
Thursday, September 19, 2019

Registration and Networking Breakfast

Developing Your Competitive Expertise: Late-Lifecyle Management & Competitive Uncertainty

inovis_150x77 Dr. Baljit Singh, Managing Director and Partner, INOVIS, Pharmaceuticals and Life Sciences Division (formerly Director, Integrated Insights, Novartis)
Dr. Satish Kumar, Head, CI Strategies, Generics & Biosimilars, INOVIS (formerly Sanofi-Genzyme)
Dr. Harshal Kubavat, Head, Strategic Consulting, Life Sciences, INOVIS (formerly Brand Manager, Roche)

Part 1: Late Lifecycle Management - Gx/Biosimilar issues, Intelligence Options, and Actions

This interactive workshop session will enable you to:
• set up a best-in-industry Gx/biosimilar RI and CI tracking program
• understand Gx / Biosimilar product development and entry strategies
• identify potential actions to optimize launches and enforce IPR / exclusivity

PART 2: Dealing with uncertainty – Delivering robust competitive assumptions with a systematic framework (Comp-ACT)

* Demonstrate the importance of comprehensive & robust threat assessments and the impacts these can have on strategic decision making (commercial readiness, development programs, BD opportunities, forecasting, scenario planning, mitigation plans, etc.)

* Provide attendees insights of a systematic framework-driven process to evaluate competitive threats from in-class/out-class competitor assets, which will ultimately ensure proactive and strategic impact

This workshop session (with breakouts), will give participants first-hand insights from combined +30 years of experience dealing with uncertainty and helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets.

Networking Lunch

Best Practices to Create/Write Effective and Impactful CI Reports and Presentations

Dave Alderman, President Molekule Consulting
Dr. Daniel Pascheles, CEO, Molekule Consulting

An “art” and “science” exists when considering clear, concise and actionable competitive strategy report writing in the biopharmaceutical space.

Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.

Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.

In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.

This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.

Networking Break and Refreshments

Leveraging Value-Added Services to Drive Profitable Growth in International Markets

Stephen Majors, Director, Healthcare Practice, DuckerFrontier
Emily Scott, Managing Director, Consulting, DuckerFrontier

The vast majority of pharma companies are not successful in using value-added services to drive profitable growth in price-constrained international markets.

Insight has a critical role to play in profiling patients/providers/patients, understanding their requirements, and creating a plan to price to value.

Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Presented by Merck

Keynote: Connected Health at the Speed of Life

Reaching and engaging the connected patient: Data first, Speed up & Provide Assistance in a mobile world

Presented by Google

Keynote: Quintessential Agency Industry Partnership – How to Make it Work!

We will role-play what a good and a more difficult agency / client relationship looks like. The goal of our “performance” is to provide the audience with an entertaining learning experience.

Topics we will cover:
• Scoping a project and preparing the brief
• Choosing an agency
• Interacting with the agency during the project
• Delivery of the project results

The audience can expect to be able to participate actively in the “conversation” and contribute to the program

Presented by Chiesi and Molekule Consulting

Refresh and Connect in Exhibition Hall

Keynote: Executive Level Discussions: Strategic CI Boardroom

A panel of CI Leaders from the following companies:

Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis

“Ask the Experts” Interactive Breakout Groups

(Explore and capture the power of participants’ Insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
Decoding Signals of Potential Disruptive Forces

Presented by Abbvie

BREAKOUT 2
Digital/Data

Presented by Novartis

BREAKOUT 3
Due Diligence Support

A substantial amount of Due Diligence goes into licensing and acquisition deals in pharma.

CI professionals play a key role in preparing for successful deals. This discussion will focus on how CI can support a large array of DD activities beyond the preparation of a competitive landscape. DD projects provide extraordinary opportunity for CI professionals to deliver outstanding value to the business by supporting and leading hosts of activities within the DD process. This discussion is intended to help raise awareness of the many ways CI can deliver value for DD projects.

Presented by Eagle Pharmaceuticals

BREAKOUT 4
Information and Insights Monet Style – Who Frames the Whole Painting?

In this session, we’ll discuss all of the various types of disparate information available to a pharma company, including CI.

In some Monet paintings, there are lots of dots of color, but only until you back-up that you see the whole picture. The question we’ll dig into is, who is putting the painting in a frame to create a cohesive picture or do we just have multiple painters with information, but no cohesiveness to it all.

Presented by Merck

BREAKOUT 5
Franchise/Marketing CI

Presented by Novartis

BREAKOUT 6
TBA

Presented by Takeda (invited)

BREAKOUT 7
Manufacturing Intelligence

Presented by ThermoFisher Scientific

BREAKOUT 8
Personal Development and Mentoring Relationships

Presented by Merck

Networking Luncheon

Think Tanks: Learning Environment

SESSION ONE

Early Stage CI and Product Pipeline

Presented by Lifescience Dynamics

SESSION TWO

Lessons from Inside Novartis, Roche, and Atacana - 5 Questions You Need to Ask to Maximize Your Success and Significantly Increase the Value of Your Competitive Intelligence

Many CI professionals fail to understand that the perceived value of their CI work is the basis for their career success.

Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders’ perception.

One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:

1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion

In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.

Presented by Atacana Group

SESSION THREE

Strategic Intelligence in an Agile World

• How do strategic and competitive intelligence need to adapt to drive value in a more agile world?

• What are the opportunities for the CI function in such a dynamic market? How can these opportunities be realized?
• What can CI functions and managers do to ensure their intelligence continues to drive value, growth, and strategy?

Presented by Deallus

Think Tanks: Learning Environment

SESSION ONE

Top 10 Challenges in CI – How to Face them Head-On

There is need for a “shake-up” in competitive intelligence.

Old-school and business-as-usual methodologies and deliverables will not cut it in an ever-changing business and technological environment that demands greater efficiencies in collection and analysis, and greater demands on ROI effectiveness of CI deliverables. As the American-Canadian writer William Gibson once said, “The future is already here – it’s just not very evenly distributed.” Prescient has surveyed CI stakeholders and has captured a list of the top challenges faced by CI teams. We will discuss the industry “norms” and the advent of budding new and futuristic solutions that will shake up the way we think of CI.

Presented by Prescient Healthcare Group

SESSION TWO

From Strategic to Predictive Intelligence – the Future is History

How the Life Science industry is using Artificial Intelligence?

How the new tools can be used to facilitate our roles within Strategic Intelligence?
How can we integrate secondary, primary and artificial intelligence for the benefit of our internal stakeholders?

Presented by GlobalReach BI

SESSION THREE

Planning for New Pharmaceutical Markets

Recent developments in the holistic pharmaceuticals market presage significant changes in the overall power dynamics.

Acquisitions such as the CVS/Aetna merger and the Walgreens/Express Scripts group purchasing alliance are indications of new trends in the market. These trends have the potential to significantly change how decisions are made in the market. This session will present a set of future scenarios that depict the market based on extension of the trends. Using interactive tools, participants will model out strategies that pharmaceutical companies will need to implement to thrive in the environment.

Key Take-aways:
1. New thinking about how the traditional pharmaceutical market will change by 2030
2. Expanded awareness of potential impacts from alliances between health insurance carriers, pharmacies, and pharmacy benefits managers
3. Exploration into ways the government can intervene in the market based on different scenarios
4. Broad strategic options for pharmaceutical companies

Presented by Fletcher/CSI

Refuel & Rejuvenate in Exhibition Hall

Leadership Insight: Case Studies

SESSION ONE

How to Be Successful as a 1-Person CI Team

Session aims to identify challenges a 1-Person CI Team faces and, ultimately, provide some potential solutions to ensure its success.

Challenges include: defining your role, understanding the expertise you bring to the table, amplifying your voice, winning buy-in, measuring your success, knowing when and how to expand.

Presented by Pfizer

SESSION TWO

Case study in using CI for Pre-launch Targeting vs Post Launch

Venturing into a new therapeutic area has its challenges especially for new products.

In the case we will look at a product launch and how initial targeting used best available data and intelligence. We will explore what happened post launch and discuss how soon should you change your strategy if the results are not what was expected. Do you need to have a wealth of data to make a change?

Presented by Amneal Pharmaceuticals

SESSION THREE

From Competitive Intelligence to Business Insights – Making CI a Core Part of Decision Making

As a competitive intelligence practitioner, seamlessly integrating competitive insights into key business decisions represents true success.

The most successful teams elevate the crucial role of competitive intelligence in informing, supporting and validating decision making. We will discuss approaches and share models of how to integrate competitive intelligence content into strategy and business activities.

Presented by Intercept Pharmaceuticals

SESSION FOUR

TBA

Presented by SK Life Science

Engagement: High Level Debate and Discussion

SESSION ONE

Strategy, BD and Market Access

Presented by Amicus Therapeutics, GlaxoSmithKline, Ionis Pharmaceuticals, Sanofi Pasteur, and Sobi

SESSION TWO

Insights into New Product Planning and Decision Making

Presented by Alnylam Pharmaceuticals, Daiichi Sankyo, Ipsen Biopharmaceuticals, Taiho Oncology, and Takeda Pharmaceuticals

SESSION THREE

Pharma and Diagnostics

Presented by Eli Lilly and Company (invited), Roche Diagnostics, Zoetis Animal Health

Drink, Eat & Be Merry! Casino Night Cocktail Reception & Networking

Registration & Networking Breakfast in Exhibition Hall

Case Histories: Sharing Experiences and Expertise

SESSION ONE

Next Generation Software CI

Presented by Abbott Laboratories

SESSION TWO

Payer Research Planning in the Era of Real World Evidence: Who Knows More About Your Product?

Presented by Insmed Incorporated

SESSION THREE

Launch Analytics: Importance in Defining Launch Strategy

The availability of granular HCP and patient level data in pharmaceutical industry helps companies take a deep dive and gain comprehensive understanding of market.

This understanding helps target the right product in order gain market share and the right customer (HCP) in order to increase promotional impact. The combination of these and other steps together helps define a winning launch strategy.

Presented by Lupin Pharmaceuticals

SESSION FOUR

TBA

Presented by Pfizer

Idea Labs: Gain New Perspectives

SESSION ONE

Social Media Monitoring and Analysis of Medical Conferences

Medical conference and tradeshow monitoring provides excellent opportunities for primary research and capture of data as soon as it is shared with the public.

The increased use of social media to share opinions regarding emerging data from conferences and tradeshows by patients, researchers, health care providers, and key thought leaders provides a new opportunity for pharmaceutical companies to improve understanding of perception related to developing and existing therapeutic approaches. While social media platforms provide basic search capabilities, subscription-based services provide the ability to analyze all social media activity from an event while offering powerful insights into user communities, influence of specific individuals, and the most widely discussed presentations and events from an event. During this presentation, we’ll share outputs from this type of analysis and share thoughts about how these activities fit into a comprehensive conference monitoring approach.

Presented by Proactive Worldwide

SESSION TWO

Ensuring Full Value from CI by Full Integration into the Strategic Planning Process

The Osprey team of strategic consultants will share experiences and perspectives on the role of the CI function in strategic planning, how to ensure CI is used well and appropriately and will provide examples of best practice from the Osprey Health Consulting wide experience of strategic planning across therapy areas.

Presented by Osprey Health Consulting

SESSION THREE

Key Issues in Managed Care and Specialty Pharmacy: Impact on the Industry

Presented by Healthcare Intelligence and Analytics

SESSION FOUR

Transformative Innovation - How ‘Big Pharma’ is Seeking to Replicate the Creativity and Nimbleness of ‘Start-up Pharma’?

Ambition horizons and investment in transformative growth

“Design Thinking” and its application across the whole organisation
Digital transformation and the rise of the Chief Digital Officer

Presented by Dig Worldwide

Refresh and Connect in Exhibition Hall

Best Practices and Insights

SESSION ONE

Looking at Competitive Intelligence through a Statistical Lens

Competitive Intelligence is most often practiced as an Art and a Science.

In this presentation we discuss how to view CI through a statistical/probabilistic lens. The discussion is motivated through the Let’s Make a Deal game show to understand how to leverage prior knowledge about an event and factor in new information through CI. The discussion will demystify Markov Chain Monte Carlo simulation methods and show how these methods can be used to help generate insights into a probability model of product launch timings. Combining launch timings with drug feature sets ( safety, efficacy and dosing ) we will show how to gain qualitative insight into NBRx. This discussion will not be a forecasting seminar and no advanced degrees are required. The objective of the talk is to provide talking points so that you can discuss with your Advanced Analytics team on how to model product launches based on competitive intelligence information and understand potential uptake of products.

Presented by Roche

SESSION TWO

Critical Success Factors in Securing CI Budget

Presented by Ionis Pharmaceuticals

SESSION THREE

Digital Therapeutics – A New ‘Pill’ar in Big Pharma

Major deals, investments, and partnerships between pharma companies and burgeoning digital therapeutic companies have become regular headline news.

What does big pharma need to know and what is being missed? How will prescription digital therapeutics (PDTs) be reimbursed? How will medical policies and drug formularies change as PDTs enter the market? As physicians, patients, and payers embrace technology to drive better treatment outcomes at lower costs, pharma companies are getting aligned to optimize their competitive positions. This session will provide the needed insight.

Presented by Click Therapeutics

SESSION FOUR

Transitioning from Vendor to Client Side

Major deals, investments, and partnerships between pharma companies and burgeoning digital therapeutic companies have become regular headline news.

CI professionals from Merck will discuss the lessons they’ve learned working both on the vendor and client side
They’ll share their thoughts on:
• How vendors view clients and how they define a successful relationship
• How clients view vendors and why they decide to work with one over another
• How to measure success
• Do’s and don’ts from both sides of the table
• Better ways to partner

Presented by Merck

“Ask the Experts” Interactive Breakout Groups

(Explore and capture the power of participants’ Insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
Decoding Signals of Potential Disruptive Forces

Presented by Abbvie

BREAKOUT 2
Digital/Data

Presented by Novartis

BREAKOUT 3
Due Diligence Support

A substantial amount of Due Diligence goes into licensing and acquisition deals in pharma.

CI professionals play a key role in preparing for successful deals. This discussion will focus on how CI can support a large array of DD activities beyond the preparation of a competitive landscape. DD projects provide extraordinary opportunity for CI professionals to deliver outstanding value to the business by supporting and leading hosts of activities within the DD process. This discussion is intended to help raise awareness of the many ways CI can deliver value for DD projects.

Presented by Eagle Pharmaceuticals

BREAKOUT 4
Information and Insights Monet Style – Who Frames the Whole Painting?

In this session, we’ll discuss all of the various types of disparate information available to a pharma company, including CI.

In some Monet paintings, there are lots of dots of color, but only until you back-up that you see the whole picture. The question we’ll dig into is, who is putting the painting in a frame to create a cohesive picture or do we just have multiple painters with information, but no cohesiveness to it all.

Presented by Merck

BREAKOUT 5
Franchise/Marketing CI

Presented by Novartis

BREAKOUT 6
TBA

Presented by Takeda (invited)

BREAKOUT 7
Manufacturing Intelligence

Presented by ThermoFisher Scientific

BREAKOUT 8
Personal Development and Mentoring Relationships

Presented by Merck

Networking Luncheon

Announcement of Raffle Prize Winners

Keynote: TBA

Presented by NYU Tandon School of Engineering (invited)

Best Practices in Action – Optimizing the Practitioner/Service Provider Partnership

As a practitioner, engaging a service provider to support a tactical or strategic initiative requires striking an optimal balance of practitioner and service provider responsibilities.

Done right, these engagements grow into partnerships resulting in actionable intelligence that can impact the bottom line as well as position your organization to strategically advise the business to better prepare it for likely scenarios ahead.

In this collaborative session, presenters will share use cases from three Fortune 100 competitive intelligence and strategy practitioners in the IT, medtech, and pharma industries that illustrate impactful approaches to an optimal symbiosis of the practitioner / service provider partnership. The focus will be on how to most effectively partner with a strategic CI service provider to both maximize the outcome of each engagement (whether it be ad hoc and tactical or longer-term and strategic) and contribute to positioning the practitioners in your organization as proactive and trusted advisors. Specific criteria and best practices for building reliable, trusted partnerships will be shared, ranging from initial rules of engagement, optimal allocation of both internal practitioner and service provider resources to engagements, and most effectively facilitating delivery of high value and high impact results.

Participants will:

• Learn frameworks for determining when to engage a service provider vs. dedicating in-house resources to an engagement; screening service providers to determine best fit; scoping and prioritizing stakeholder needs prior to deploying a service provider; and providing targeted, actionable deliverables

• Hear real-world examples from practitioners who have built up efficient and trusted partnerships with CI and strategy service providers, including practical ROI measures and CI outputs’ specific impact on strategic and tactical decisions

• Hear a CI and strategy vendor’s perspective on key success factors for establishing and growing a flourishing and rewarding practitioner/service provider relationship, including a hands-on toolbox for implementable strategies

• Actively participate in a group exercise to distill top practical applications and best practices from the session

Presented by INOVIS

Livepolling Power Panel: Review and Discussion of the Most Controversial and Important Topics During the Two Days

A panel of CI Leaders from the following companies:

Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis

Conference Concludes